Targeted therapy (Nivolumab and Trametinib later switched to Ivosidenib) was also started for BC25, a girl with a primary MMR-deficient IDH-mutant astrocytoma due to a heterozygous germline MSH2 variant. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).